0007j0.Kq
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, though it has not disclosed specific products or revenue sources in the latest financial filings.
Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, though it has not disclosed specific products or revenue sources in the latest financial filings.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, though it has not disclosed specific products or revenue sources in the latest financial filings.
The company maintains a strong liquidity position, with a current ratio of 93.84, indicating that it holds significantly more current assets than current liabilities. However, it is experiencing negative operating and free cash flows, with operating cash flow at -4.49 billion KRW and free cash flow at -5.78 billion KRW, which may signal ongoing operational challenges.
Profitability metrics are negative, with a return on equity of -28.69% and a return on assets of -27.15%. These figures are well below the typical performance of the biotechnology industry, which generally expects positive returns during periods of R&D investment and commercialization. The company is currently operating at a loss, with a net income of -6.04 billion KRW and an operating income of -6.37 billion KRW.
The company's revenue is reported as zero, and no specific segments or geographic regions are disclosed in the latest financial data. This lack of segmentation makes it difficult to assess the geographic or product-based concentration of its operations. However, the absence of revenue and the negative cash flows suggest a high concentration of risk in its current business model.
The company's growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance. The absence of revenue and the negative operating performance indicate a potential decline in business activity. The company is not disclosing any specific growth initiatives or strategic plans in the latest filings.
The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a very low debt-to-equity ratio of 0.01, suggesting minimal leverage and a strong equity position. However, the negative cash flows and operating losses may pose long-term liquidity risks if not addressed.
No recent events, such as filings or transcripts, are disclosed in the available data. The company has not provided any public commentary or updates on its operations or financial strategy in the latest available documents.
- The company has a strong liquidity position but is experiencing significant negative cash flows and operating losses.
- Profitability metrics are negative, with return on equity and return on assets well below industry norms.
- The company's revenue is reported as zero, and no specific segments or geographic regions are disclosed.
- Growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance.
- Risk assessment indicates low liquidity and dilution risk, but the negative cash flows may pose long-term liquidity concerns.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- 0007J0.KQ Market data — financials · 2026-05-26
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
4 tracked-field change(s) detected vs prior analysis; max severity: medium.
- Dilution risk— → lowlow
- Liquidity risk— → lowlow
- Activity— → Pharmaceuticals & Medical Researchmedium
- Economic sector— → Healthcaremedium